Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Elite Feature: Find Similar Charts in Seconds

VivoSim Labs, Inc.

Contributing Author

Recent Articles by VivoSim Labs, Inc.

Sep-16	VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs VIVS GlobeNewswire
Sep-01	VivoSim Labs to Add Rat Liver Model to NAMkind Platform VIVS GlobeNewswire
Aug-06	VivoSim Provides Financial and Listing Compliance Update VIVS -9.24% GlobeNewswire
Jul-21	VivoSim Enters China with First Commercial Sales of NAMkind Toxicology Screening and Efficacy Testing Services VIVS -10.87% GlobeNewswire
Jul-16	VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor VIVS -28.06% GlobeNewswire
Jul-15	VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 VIVS GlobeNewswire
Jun-29	VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting VIVS GlobeNewswire
Apr-28	VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results - Without Animal Testing VIVS GlobeNewswire
Apr-01	VivoSim Announces Pricing of up to a $4 Million Public Offering VIVS +13.29% GlobeNewswire
Mar-24	VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs VIVS GlobeNewswire
Mar-03	VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales VIVS -12.73% GlobeNewswire
Feb-11	VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego VIVS GlobeNewswire
Jan-29	VivoSim Expands Asia-Pacific Access to NAMKind Human-Based Toxicology Services Through New Distributor Agreement in Korea and China VIVS VIVS +71.76% GlobeNewswire
Jan-06	VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer VIVS GlobeNewswire
Aug-14	VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer VIVS GlobeNewswire
May-13	VivoSim's NAMKind Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference VIVS GlobeNewswire
May-07	VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference VIVS GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)